XTNT Xtant Medical Holdings, Inc.
XASE
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XASE
- Market Cap
- $0.0B
- Employees
- 151
- List Date
- 2007-01-31
- CIK
- 0001453593
- Next Earnings
- 2026-11-09
- Headquarters
- Belgrade, MT
- Homepage
- http://www.xtantmedical.com
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other al…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 19.51% | -5.72% | 6.51% | -23.97% | 31.36% | -20.75% | 1.16% |
| Feb | 190.60% | 29.97% | 29.99% | 3.77% | -15.02% | -5.11% | 39.03% |
| Mar | -42.30% | -10.34% | -34.95% | 0.00% | 4.44% | -2.35% | -14.25% |
| Apr | -21.21% | -7.30% | -3.09% | -13.15% | 8.08% | -1.65% | -6.39% |
| May | -18.89% | -8.71% | -0.31% | -16.38% | 40.79% | -15.92% | -3.24% |
| Jun | 12.41% | -11.93% | 50.27% | -13.35% | 11.82% | -8.91% | 6.72% |
| Jul | -30.90% | 6.23% | 18.69% | 13.53% | -19.86% | 1.85% | -1.74% |
| Aug | -3.08% | 1.04% | 14.29% | 7.40% | 14.11% | -10.91% | 3.81% |
| Sep | -11.20% | 24.10% | -16.67% | 22.69% | 3.41% | -3.51% | 3.14% |
| Oct | 2.68% | -9.97% | 1.74% | -15.32% | 36.06% | -22.33%* | -1.19% |
| Nov | -39.69% | -5.52% | 5.98% | -25.11% | -27.25% | -- | -18.32% |
| Dec | -21.23% | 12.59% | -13.08% | 10.75% | 32.77% | -- | 4.36% |
| Total | -58.24% | 4.46% | 38.52% | -47.84% | 146.54% | -62.39% | 3.51% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: XTNT
Executive Summary
BULLISH (Confidence Level: 7)
Key drivers:
- Strong fundamental performance with record revenue in FY2023
- Low volatility, indicating reduced risk
Primary risks:
- Divergence between technical and news signals
- Potential for mean reversion or consolidation
Investment thesis: XTNT is a stable company with growing fundamentals, poised to continue its upward trend. However, we caution that the stock may experience some volatility due to market conditions.
Recent news sentiment impact: The recent positive earnings release has contributed to the bullish sentiment.
Technical Analysis
Trend Direction: Neutral (1-4 weeks), Medium-term (1-3 months)
Support/Resistance Levels:
- Resistance: $0.48 (Upper Bollinger Band)
- Support: $0.43 (Lower Bollinger Band)
Momentum Signals:
- RSI: 40.98 (Neutral)
- MACD: Bearish signal, but showing signs of weakening
- Bollinger Bands: Neutral signal, with price touching the middle band
Volume Analysis:
- Volume SMA 20: 141074.56 (stable volume)
- On-Balance Volume (OBV): 3201612.35 (increasing buying pressure)
News & Sentiment Analysis
Recent Headlines Summary: Neutral sentiment with a focus on corporate developments and financial performance.
Sentiment Assessment: Positive
Catalyst Identification:
- Earnings release on April 1, 2024
- Investor conferences in the near future (no specific dates provided)
Market Narrative: The recent positive earnings release has contributed to the bullish sentiment, which aligns with our technical analysis.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta = 0.73)
Volatility Regime: Low volatility - stock moves less than market
Options Market Signals:
- IV Premium vs HV30: N/A (no data available)
- Put/call ratios: No unusual activity detected
- Unusual activity: No significant events reported
Downside Protection:
- Support levels: $0.43 (Lower Bollinger Band)
- Risk management considerations: Consider a stop-loss level at $0.40 to manage risk.
Market Context & Positioning
Sector Performance: XTNT is outperforming its sector peers, indicating a strong relative performance.
Institutional Activity: No unusual institutional activity detected.
Correlation Analysis: Low correlation with market (R-squared = 0.15)
Relative Valuation: The stock is trading within a reasonable range.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $0.48 (Upper Bollinger Band)
- Support: $0.43 (Lower Bollinger Band)
Breakout/Breakdown Levels: None detected
Time-Sensitive Catalysts: Earnings release on April 1, 2024, and investor conferences in the near future.
Risk Management: Consider a stop-loss level at $0.40 to manage risk.
This comprehensive analysis provides an objective evaluation of XTNT's technical and fundamental performance, highlighting key drivers, primary risks, and recent news sentiment impact.
XTNT Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Low volatility - stock moves less than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $394K | #2694 of 3138 | -5.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $81K | #5869 of 6285 | +18.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $36K | #3695 of 3716 | -36.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
XTNT Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
XTNT Insider Trading (Form 4)
Latest: 2026-08-18| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Abhinav Jain | Director | Award (A) | +215,517 | — | EDGAR | |
| 2026-08-18 | Scott C Neils | CFO and Assistant Secretary | Mixed | +371,845 | $0.31 | -$8.7K | EDGAR |
| 2026-08-18 | Jonn R. Beeson | Director | Award (A) | +215,517 | — | EDGAR | |
| 2026-08-18 | Sean E Browne | President and CEO | Mixed | +539,395 | $0.31 | -$3.3K | EDGAR |
| 2026-08-18 | Mark A. Schallenberger | Chief Operating Officer | Mixed | +442,930 | $0.31 | -$2.2K | EDGAR |
| 2026-08-18 | John K Bakewell | Director | Award (A) | +215,517 | — | EDGAR | |
| 2026-08-18 | Stavros G. Vizirgianakis | Director | Award (A) | +323,275 | — | EDGAR | |
| 2026-08-18 | Tyler Lipschultz | Director | Award (A) | +215,517 | — | EDGAR | |
| 2026-02-18 | Mark A. Schallenberger | Chief Operating Officer | Tax (F) | −7,709 | $0.58 | -$4.5K | EDGAR |
| 2026-01-16 | Scott C Neils | CFO and Assistant Secretary | Tax (F) | −8,084 | $0.65 | -$5.3K | EDGAR |
| 2025-11-18 | Tyler Lipschultz | Director | Award (A) | +158,228 | — | EDGAR | |
| 2025-11-18 | John K Bakewell | Director | Award (A) | +158,228 | — | EDGAR | |
| 2025-11-18 | Stavros G. Vizirgianakis | Director | Award (A) | +553,797 | — | EDGAR | |
| 2025-11-18 | Scott C Neils | CFO and Assistant Secretary | Award (A) | +263,291 | — | EDGAR | |
| 2025-11-18 | Jonn R. Beeson | Director | Award (A) | +158,228 | — | EDGAR |
XTNT Insider Holdings
8 insiders · @ $0.28| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Stavros G. Vizirgianakis | Director | 7,838,845 | $2.16M | $1.09M | 7 | 2026-08-18 |
| 2 | Sean E Browne | President and CEO | 3,125,274 | $859.8K | -$85.8K | 13 | 2026-08-18 |
| 3 | Jonn R. Beeson | Director | 1,748,408 | $481.0K | $0 | 5 | 2026-08-18 |
| 4 | Scott C Neils | CFO and Assistant Secretary | 1,243,381 | $342.1K | -$8.3K | 12 | 2026-08-18 |
| 5 | John K Bakewell | Director | 1,129,633 | $310.8K | $0 | 10 | 2026-08-18 |
| 6 | Mark A. Schallenberger | Chief Operating Officer | 1,113,157 | $306.2K | $0 | 7 | 2026-08-18 |
| 7 | Tyler Lipschultz | Director | 373,745 | $102.8K | $0 | 2 | 2026-08-18 |
| 8 | Abhinav Jain | Director | 373,745 | $102.8K | $0 | 2 | 2026-08-18 |
XTNT Board & Officers
As of SEC filings through Aug 18, 2026Directors 6
- John K Bakewell · since Feb 13, 2018
- Sean E Browne · listed since Nov 2020
- Stavros G. Vizirgianakis · since Aug 25, 2022
- Jonn R. Beeson · since May 1, 2023
- Abhinav Jain · since Aug 1, 2025
- Tyler Lipschultz · since Aug 1, 2025
Officers 3
- Sean E Browne · President and CEO · since Oct 7, 2019
- Scott C Neils · CFO and Assistant Secretary · listed since Nov 2025
- Mark A. Schallenberger · Chief Operating Officer · listed since Nov 2025
Changes in the last 10 years (47)
| Nov 18, 2025 | Scott C Neils listed as CFO and Assistant Secretary (previously Chief Financial Officer) in SEC filings |
| Nov 18, 2025 | Mark A. Schallenberger listed as Chief Operating Officer (previously Chief Operations Officer) in SEC filings |
| Aug 1, 2025 | Tyler Lipschultz became a director |
| Aug 1, 2025 | The company announced the departure of Robert McNamara from the board in an SEC filing |
| Aug 1, 2025 | The company announced the departure of Lori D Mitchell-Keller from the board in an SEC filing |
| Aug 1, 2025 | Abhinav Jain became a director |
| Apr 14, 2025 | Orbimed ROF II LLC reported in an SEC filing no longer being a director |
| Apr 14, 2025 | Orbimed ROF II LLC reported in an SEC filing no longer being a 10% owner |
| Apr 14, 2025 | Orbimed Advisors LLC reported in an SEC filing no longer being a director |
| Apr 14, 2025 | Orbimed Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Apr 10, 2025 | Wilmot B. Harkey became a 10% owner |
| Apr 10, 2025 | Nantahala Capital Partners Limited Partnership became a 10% owner |
| Apr 10, 2025 | Nantahala Capital Management, LLC became a 10% owner |
| Apr 10, 2025 | Daniel Mack became a 10% owner |
| Aug 19, 2024 | Kevin D Brandt reported in an SEC filing no longer being Chief Commercial Officer |
| May 16, 2023 | Lori D Mitchell-Keller became a director |
| May 1, 2023 | The company announced the departure of Michael Eggenberg from the board in an SEC filing |
| May 1, 2023 | The company announced the departure of Matthew Rizzo from the board in an SEC filing |
| May 1, 2023 | Jonn R. Beeson became a director |
| Jan 16, 2023 | Mark A. Schallenberger became Chief Operations Officer |
| Aug 25, 2022 | Stavros G. Vizirgianakis became a director |
| Aug 23, 2022 | The company announced the departure of Jeffrey J Peters from the board in an SEC filing |
| Aug 17, 2022 | Scott C Neils listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Jan 3, 2022 | The company announced the departure of Greg Jensen as VP, Finance & CFO in an SEC filing |
| Jan 3, 2022 | Scott C Neils became Interim CFO |
| Nov 16, 2020 | Sean E Browne first listed as a director in an SEC filing |
| Oct 7, 2019 | Sean E Browne became President and CEO |
| Aug 16, 2019 | Kevin D Brandt listed as Chief Commercial Officer (previously VP & Chief Commercial Officer) in SEC filings |
| Aug 16, 2019 | Greg Jensen listed as VP, Finance & CFO (previously VP, Finance and Interim CFO) in SEC filings |
| Apr 3, 2019 | Orbimed ROF II LLC first on file as a director |
| Apr 3, 2019 | Orbimed ROF II LLC first on file as a 10% owner |
| Feb 11, 2019 | Greg Jensen became VP, Finance and Interim CFO |
| Jan 1, 2019 | Ronald G. Berlin became VP & Chief Operations Officer |
| Oct 15, 2018 | Michael Mainelli first listed as Interim CEO in an SEC filing |
| Aug 20, 2018 | Kathie J. Lenzen became SVP Fiance & Admin. & CFO |
| Jul 9, 2018 | Kevin D Brandt became VP & Chief Commercial Officer |
| Feb 23, 2018 | Orbimed Advisors LLC first listed as a director in an SEC filing |
| Feb 13, 2018 | Robert McNamara became a director |
| Feb 13, 2018 | Michael Mainelli became a director |
| Feb 13, 2018 | Michael Eggenberg became a director |
| Feb 13, 2018 | Michael Eggenberg became a 10% owner |
| Feb 13, 2018 | Matthew Rizzo became a director |
| Feb 13, 2018 | Matthew Rizzo became a 10% owner |
| Feb 13, 2018 | John K Bakewell became a director |
| Feb 13, 2018 | Jeffrey J Peters became a director |
| Jan 17, 2018 | Samuel D Isaly became a 10% owner |
| Jan 17, 2018 | Orbimed Advisors LLC became a 10% owner |
- Prev
- 1
Not reported recently (18)
- Daniel Mack · Last reported as a 10% owner in an SEC filing dated Apr 17, 2025
- Wilmot B. Harkey · Last reported as a 10% owner in an SEC filing dated Apr 17, 2025
- Nantahala Capital Management, LLC · Last reported as a 10% owner in an SEC filing dated Apr 17, 2025
- Nantahala Capital Partners Limited Partnership · Last reported as a 10% owner in an SEC filing dated Apr 17, 2025
- Michael Eggenberg · Last reported as a 10% owner in an SEC filing dated Aug 17, 2022
- Matthew Rizzo · Last reported as a 10% owner in an SEC filing dated Aug 17, 2022
- Ronald G. Berlin · Last reported as VP & Chief Operations Officer in an SEC filing dated Jan 16, 2019
- Michael Mainelli · Last reported as a director in an SEC filing dated Oct 15, 2018
- Kathie J. Lenzen · Last reported as SVP Fiance & Admin. & CFO in an SEC filing dated Sep 18, 2018
- Carl O'Connell · Last reported as President in an SEC filing dated Aug 16, 2018
- Samuel D Isaly · Last reported as a 10% owner in an SEC filing dated Jan 19, 2018
- Kent L Swanson · Last reported as a director in an SEC filing dated Jul 27, 2017
- Michael A Lopach · Last reported as a director in an SEC filing dated Jul 27, 2017
- John Arthur Deedrick · Last reported as a director in an SEC filing dated Jul 27, 2017
- Eric Bernard Timko · Last reported as a director in an SEC filing dated Jul 27, 2017
- Rudy A Mazzocchi · Last reported as a director in an SEC filing dated Jul 27, 2017
- Paul Buckman · Last reported as a director in an SEC filing dated Jul 27, 2017
- Daniel S Goldberger · Last reported as a director in an SEC filing dated Nov 25, 2016
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.